3D Tissue Models
4th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes

4325 Alexander Drive
Alpharetta, GA

Schedule of Presentations:

Thursday, November 8, 2007
08:15:00 Welcome and Introduction
08:30:00 Classification and morphology of myelodysplastic diseases Attilio Orazi
09:00:00 Event-associated (secondary) myelodysplasia John M. Bennett
09:30:00 Update on lenalidomide and other drugs Alan F. List
10:00:00 Arsenic in MDS Gail J Roboz
10:30:00 Coffee break
11:00:00 What transplant and when for patients with MDS H. Joachim Deeg
11:30:00 Keynote address: Lessons from kinase inhibitors Charles L Sawyers
12:15:00 Panel discussion
12:30:00 Lunch
13:30:00 The role of JAK2V617F mutation in the pathogenesis and progression of myelofibrosis with myeloid metaplasia Giovanni Barosi
14:00:00 NF-E2 in the pathophysiology of MPDs Heike L Pahl
14:30:00 Is this a disease of the stem cell niche? Ronald Hoffman
15:00:00 Coffee break
15:30:00 Clinical and therapeutic implications of megakaryocyte-stem cell niche deregulation in primary myelofibrosis Marie-Caroline Le Bousse-Kerdilès
16:00:00 Transplantation in myelofibrosis Francisco Cervantes
16:30:00 Treatment of myelofibrosis diseases: Current challenges and future prospects Ruben A Mesa
17:00:00 Panel discussion
17:15:00 Adjourn
Friday, November 9, 2007
08:30:00 Genetics of myeloproliferative disorders with emphasis on ET Radek Skoda
09:00:00 Erythrocytosis: Congenital and nonclonal Josef T Prchal
09:30:00 JAK2V617F allele burden: Clinical correlates and genetic modifiers Alison R. Moliterno
10:00:00 Coffee Break
10:30:00 Risk factors for survival, leukemic transformation, and thrombosis in essential thrombocythemia and polycythemia vera: Mayo clinic experience Ayalew Tefferi
11:00:00 Mutation of JAK2V617F and clonality studies in the myeloproliferative disease Peter Campbell
11:30:00 “Modern” management of polycythemia vera Richard T. Silver
12:00:00 Panel discussion/questions
12:15:00 Luncheon Symposium
13:30:00 Molecular drug targets in myeloproliferative disorders D. Gary Gilliland
14:00:00 Pathogenesis and management of ET Anthony R. Green
14:30:00 Leukocytosis and the risk of thrombosis in ET & PV Tiziano Barbui
15:00:00 Coffee Break
15:15:00 BCR-ABL negative atypical myelopro­liferative diseases Nick C.P Cross
15:45:00 The fallacy of the partial cytogenetic response Vesna Najfeld
16:15:00 How can one mutation explain 3 different MPDs? Chloe James
16:45:00 Selected abstracts and poster review Jerry L. Spivak
17:45:00 Adjourn
Saturday, November 10, 2007
08:30:00 Inhibiting BCR-ABL signal trans­duction: BCR-ABL formation, mechanisms of action of the different TK inhibitors, possible downstream targets for therapy Giuseppe Saglio
09:00:00 Imatinib updated: Clinical data, dosage, toxicity, stopping, pregnancy and case history Hagop M. Kantarjian
09:30:00 Monitoring response to therapy: Cytogenetics and PCR, defining response and failure and case history John Goldman
10:00:00 Break
10:30:00 Imatinib resistance: Classifications and mechanisms of resistance D. Gary Gilliland
11:00:00 Second and third generation tyrosine kinase inhibitors: Initial clinical results and toxicity, and case history Jorges Cortes
11:30:00 Prospective clinical trials: Questions to be addressed in 2007 (useable endpoints, statistical considerations, survey of German and international phase III studies) Rudiger Hehlmann
12:00:00 Panel discussion
12:15:00 Adjourn
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.